Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May;73(5):390-401.
doi: 10.1111/aji.12341. Epub 2014 Dec 2.

Purified IgG from patients with obstetric but not IgG from non-obstetric antiphospholipid syndrome inhibit trophoblast invasion

Affiliations

Purified IgG from patients with obstetric but not IgG from non-obstetric antiphospholipid syndrome inhibit trophoblast invasion

Katie Poulton et al. Am J Reprod Immunol. 2015 May.

Abstract

Problem: Some patients with antiphospholipid syndrome (APS) suffer pregnancy morbidity (PM) but not vascular thrombosis (VT), whilst others suffer VT only. Therefore, we compared the effects of IgG from VT+/PM- and VT-/PM+ subjects on human first-trimester trophoblast (HTR8) cells.

Method of study: HTR-8 cells were incubated with APS VT+/PM-, APS VT-/PM+ or healthy control (HC) IgG. We measured trophoblast invasion by cell invasion assay; mRNA expression of TLR4 and adaptor proteins; phosphorylation of p38 MAPK, NFκB and ERK; and expression of interleukin (IL)-8 and IL-6.

Results: VT-/PM+ IgG, but not VT+/PM- IgG significantly reduced HTR-8 invasion. The effects on invasion were blocked by TLR-4 inhibition. Neither VT+/PM- nor VT-/PM+ IgG altered MyD88 mRNA expression, phosphorylation of signalling molecules or cytokine expression.

Conclusions: VT-/PM+ IgG exert functionally relevant effects on human trophoblast cells but VT+/PM- IgG do not.

Keywords: Antiphospholipid; TLR4; obstetric; trophoblast.

PubMed Disclaimer

Figures

Figure 1
Figure 1
IgG purified from patients with VT−/PM+ APS inhibit HTR-8 cell invasion, which is abrogated when cells are treated with a TLR4 inhibitor. The ability of HTR-8 cells to invade after treatment with 100 μg/mL pooled IgG from VT+/PM− with 83.7 GPLU and 66.0SU binding activity, VT−/PM+ with 47.2GPLU and 63.8SU binding activity and HCs with 0GPLU and SU binding (a) and following pre-treatment with the TLR4 inhibitor CLI-095 or TLR4 antagonist, Ultra Pure Rhodobacter sphaeroides LPS (b) was measured using a transwell invasion assay after 48 hr. HC cell invasion was set at 100%, and the relative invasion of HTR-8 cells exposed to APS-IgG was analysed from this. Graph shows mean ± SEM of quantitative analysis from six (a) and three (b) independent experiments. Statistical analysis was performed as follows: (a) one-way anova (P = 0.01) with Dunn's multiple comparisons test (*P < 0.05); (b) one-way anova (P = 0.03) with Dunn's multiple comparisons test (*P < 0.05).
Figure 2
Figure 2
HTR-8 cells treated with VT−/PM+ IgG but not HTR-8 cells treated with VT+/PM− IgG increase TLR4 and TRIF transcript levels. HTR-8 cells were treated with 100 μg/mL pooled IgG from VT+/PM− with 78.2GPLU and 44.4SU binding activity, VT−/PM+ with 83.4GPLU and 71.5SU binding activity and HCs with 0GPLU and SU binding. TLR4 (a), TRIF (b) and MyD88 (c) mRNA expression at 6 hr was measured by qRT-PCR. TRIF mRNA expression in HTR-8 cells pre-treatment with the TLR4 inhibitor CLI-095 before treatment with 100 μg/mL pooled IgG from VT+/PM−, VT−/PM+ and HCs was also measured (d). The mean ± SEM of quantitative analysis from four independent experiments is shown. Results are expressed as fold change of either TLR4, TRIF or MyD88/GAPDH, relative to untreated cells. No statistically significant differences were found by one-way anova.
Figure 3
Figure 3
APS-IgG do not increase the phosphorylation of p38 MAPK, NFκB p65 or ERK. HTR-8 cells were treated with 100 μg/mL pooled IgG from VT+/PM− with 78.2GPLU and 44.4SU binding activity, VT−/PM+ with 83.4GPLU and 71.5SU binding activity and HCs with 0GPLU and SU binding as well as the positive controls TNF-α (10 ng/mL). Graphs show relative expression at 15 min of p38 MAPK (a), NFκB p65 (b) and ERK (c). The mean ± SEM of quantitative analysis from three independent experiments is shown. No statistically significant differences were found by one-way anova.
Figure 4
Figure 4
APS-IgG do not increase the transcript or protein secretion of the cytokines IL-8 and IL-6 in HTR-8 cells. HTR-8 cells were treated with 100 μg/mL pooled IgG from VT+/PM− with 83.7 GPLU and 66.0SU binding activity, VT−/PM+ with 47.2GPLU and 63.8SU binding activity and HCs with 0GPLU and SU binding as well as the positive controls TNF-α (10 ng/mL). Graphs (a–d) show qRT-PCR analysis of IL-8 (a), and IL-6 (c) mRNA expression at 6 hr and ELISA results of IL-8 (b) and IL-6 (d) protein expression at 72 hr. The mean ± SEM of quantitative analysis from four independent experiments is shown. No statistically significant differences were found by one-way anova.

References

    1. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quere I, Hachulla E, Vasconcelos C, Roch B, Fernandez-Nebro A, Boffa MC, Hughes GR, Ingelmo M. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–1027. - PubMed
    1. Rai RS. Antiphospholipid syndrome and recurrent miscarriage. J Postgrad Med. 2002;48:3–4. - PubMed
    1. Backos M, Rai R, Baxter N, Chilcott IT, Cohen H, Regan L. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. Br J Obstet Gynaecol. 1999;106:102–107. - PubMed
    1. Sebire NJ, Fox H, Backos M, Rai R, Paterson C, Regan L. Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure. Hum Reprod. 2002;17:1067–1071. - PubMed
    1. Sebire NJ, Backos M, El Gaddal S, Goldin RD, Regan L. Placental pathology, antiphospholipid antibodies, and pregnancy outcome in recurrent miscarriage patients. Obstet Gynecol. 2003;101:258–263. - PubMed

Publication types

MeSH terms

Substances